Art, Surgery and Transplantation

Professor Sir Roy Calne, F.R.S.
University of Cambridge, UK

Professor Sir Roy Calne is recognised as one of the world’s leading transplant surgeons and also as a gifted artist. He has played an influential role in the development of transplantation surgery and has pioneered the use of the two main drugs used to prevent graft rejection, azathioprine (Imuran®) and cyclosporin (Sandimmun® and Neoral®). He now heads one of the leading transplant centres in the world and actively campaigns to increase public awareness of the benefit of transplantation techniques.

In addition, art and painting have always been a major influence in his life. His early work consisted of landscapes and still life studies, however, in recent years he has concentrated on producing portraits of his patients and colleagues at Addenbrooke’s Hospital, Cambridge, UK.

Art, Surgery and Transplantation describes Professor Calne’s experiences in the field of transplantation, how art affects the work of a surgeon and the perspectives of the transplant patient and donor. The text is beautifully illustrated with over one hundred of his paintings depicting all aspects of transplant surgery.
For relevant coverage on all aspects of geriatric health care, your best resource is the official journal of the American Geriatrics Society. No other journal can match it for experience and authority.

- Illuminating articles on basic and clinical research.
- Insight and answers on difficult ethical questions.
- Reliable reports on legislative and judicial developments influencing patient protocols.
- Perspectives on health care policy, education, clinical management, and research.
- Practical solutions to common problems.
- Updates on trends in research and patient management.

4 EASY WAYS TO ORDER

CALL 1-800-638-6423
Outside the U.S.: 410-528-8555
London: 171-543-4848
Hong Kong: 852-2610-2339
Tokyo: 03-5688-5400

FAX 410-528-8596
E-MAIL custserv@w1wilkins.com

MAIL order form today to:
Williams & Wilkins
P.O. Box 23291
Baltimore, MD 21203-9990
Williams & Wilkins' gift certificates let you do your giving with a professional touch. Certificates are available in $25 and $50 denominations and are good toward the purchase of any of our fine line of books, journals, videos, CD-ROMs, or software.

These certificates are perfect for students, residents, or your colleagues. They're a personalized gift that lets you show your commitment to excellence in medicine.

Redeeming these gift certificates is easy — recipients just choose the product they want by reviewing our catalog, website, promotional brochures, or calling our customer service department. They then return the gift certificate to Williams & Wilkins after making their product selection.

These certificates are just like the ones available at retail stores and they're good for any Williams & Wilkins product. This is one gift of knowledge your friends and colleagues will remember for many years.

To order or redeem your gift certificates call 1-800-638-0672.

Outside North America call 410-528-4223 or fax 410-528-8550

Visit our website:
http://www wwilkins.com or send us
E-mail: custserv@wwilkins.com.
At the top of your professional reading list

Yes, enter my subscription to The Journal of Urology.

In the U.S.
- Individual $332/year
- Institutional $367/year
- In-training $182/year
Outside the U.S.
- Individual $447/year
- Institutional $492/year
- In-training $285/year

Payment options:
- New Subscription
- Renewal
- Bill me
- Check enclosed (payable to Williams & Wilkins)
- AmEx
- MC
- Visa
- Discover

Card 
Exp. date

Signature/Proxy 
Name 
Address 

City/State/Zip/Country

MD subscribers add state sales tax. Orders outside the U.S. must be prepaid in U.S. dollars only. Rates valid through October 31, 1998.

*Please specify institution & training status

AUA members receive the journal as a benefit of their membership.

Return this coupon to: Williams & Wilkins, A Waverly Company, P.O. Box 23291, Baltimore, MD 21203-9990.

For credit card orders, call TOLL FREE 1-800-638-6423 from anywhere in North America.

Every month, you get comprehensive, all-inclusive coverage with the unique blend of articles, reviews, and lively commentary in The Journal of Urology. Be in touch with the breaking developments and innovative clinicians and researchers who shape the way you practice every day. Each issue brings you an average of:

1 review article summarizing state-of-the-art research and practice.

40 original clinical articles addressing your primary concerns...including urologic neurology and urodynamics.

10 pediatric urology articles

12 case reports filled with practical diagnostic and management articles and developments in innovative clinical procedures.

15 investigative articles bringing you up-to-date on progress in solving urology's toughest clinical and theoretical problems.

75 abstracts to keep you abreast of the latest, most significant developments in every area of urology.

And now, The Journal of Urology is even more valuable to your practice. Earn up to 24 hours of Category 1 credit, offered by the American Urological Association Office of Education. For a small registration fee, you receive answer sheets for the questions published in each issue based on that month's articles. Subscribe to The Journal of Urology now and receive more than 5,000 pages of the latest information for urologists and the opportunity to earn CME credits at your convenience.

4 easy ways to order

Call 1-800-638-6423

Outside the U.S.: 410-528-8555
London: 171-543-4848
Hong Kong: 852-2610-2539
Tokyo: 03-5689-5400

Fax 410-528-8596

E-Mail: custserv@wwilkins.com

Mail order form today to:

Williams & Wilkins
P.O. Box 23291
Baltimore, MD 21203-9990

Members of the AUA receive the Journal as a benefit of membership.
The Most Influential Journal in the Field

Transplantation®

Official Journal of the Transplantation Society

Published twice monthly, this frequently cited scientific journal features comprehensive coverage of the important advances in transplantation surgery.

Expert researchers and clinicians contribute formal papers and brief abstracts in every pertinent specialty, ranging from hematology and endocrinology to genetics and embryology. You'll get current insights on...

- experimental and clinical transplantation
- immunobiology
- immunogenetics
- histocompatibility
- tissue antigens

Ranking first for impact among 9 transplantation journals and fourth for impact among 103 journals in the surgery category (Science Citation Index, 1995), TRANSPLANTATION will prepare you for the future of the field.

4 Easy Ways To Order

- Call 1-800-638-6423
  Outside the U.S.: 410-528-8555
  London: 171-543-4848
  Hong Kong: 852-2610-2339
  Tokyo: 03-5609-4000
- Fax 410-528-8596
- E-Mail custserv@wwilkins.com
- Mail order form today to:
  Williams & Wilkins
  P.O. Box 23291
  Baltimore, MD 21203-9990

Yes, start my subscription to Transplantation®. 24 times a year.

- Individual $351/year
- Institutional $565/year
- In-training *$208/year
  (Add $80 yr. outside the U.S. in Canada also add GST and HST)

- New Subscription
- Renewal
- Subscribe for up to 3 years at the current rate!

- 3 years
- 2 years
- 1 year

Payment Options: 
- Bill me
- Check enclosed (payable to Williams & Wilkins)
- Am Ex MC VISA Discover

Card # Exp. date

Signature/ID: #

Name

Address

City/State/Zip

Country

MD subscribers add state sales tax. Orders outside the U.S. must be prepaid in U.S. dollars only. Rates valid through October 31, 1998.

* Please specify institution & training status

http://www.wilkins.com
Here's your chance to complete your professional reading list with the most comprehensive, most significant journal in the field of alcoholism studies—Alcoholism: Clinical and Experimental Research.

Nine times a year, you'll get original research articles on alcoholism, alcohol-induced syndromes, and organ damage. The basic sciences—including biochemistry, experimental neurology and psychology, psychiatry, and physiology—are all represented, as are clinical science (including epidemiology and work with human subjects) and the therapeutic professions. Expert critiques of timely publications, abstracts from important international meetings, and society news and announcements complete this invaluable update.

As the leading journal in the substance abuse category, Alcoholism attracts some of the finest minds in research today. Distinguished editors from The Research Society on Alcoholism carefully select all the important results you need for your laboratory or office work. Pharmacologists, toxicologists, researchers, psychiatrists, neuroscientists, and physicians with an interest in alcoholism research and liver disease, will find Alcoholism a valuable resource.

EASY WAYS TO ORDER

CALL 1-800-638-6423
Outside the U.S.: 410-528-8555
London: 171-543-4848
Hong Kong: 852-2610-2339
Tokyo: 03-5689-5400

FAX 410-528-8596

E-MAIL custserv@wwilkins.com

MAIL order form today to:
Williams & Wilkins
P.O. Box 23291
Baltimore, MD 21203-9990

Please enter my subscription to Alcoholism: Clinical and Experimental Research. Nine times a year.

☐ Individual $215/year
☐ Institutional $415/year
☐ In-training* $130/year

(Add $45/yr outside the U.S. in Canada, add GST and HST.)
☐ New Subscription ☐ Renewal
Subscribe for up to 3 years at the current rate!
☐ 3 years ☐ 2 years ☐ 1 year

PAYMENT OPTIONS:
☐ Check enclosed (payable to Williams & Wilkins)
☐ AmEx ☐ MC ☐ VISA ☐ Discover

Card # Exp. Date
Signature/P.O. #

Phone #

Name

Address

City/State/Zip

Country

MD subscribers add state sales tax. Orders outside the U.S. must be prepaid in U.S. dollars only. Rates valid through October 31, 1998.

*Please specify institution & training status
BRIEF SUMMARY

RECOMBIVAX HB®
HEPATITIS B VACCINE (RECOMBINANT)

Please read the full Prescribing Information for complete details.

INDICATIONS AND USAGE

RECOMBIVAX HB is indicated for vaccination against infection caused by all known subtypes of hepatitis B virus. RECOMBIVAX HB Dialysis Formulation is indicated for vaccination of adult predialysis and dialysis patients against infection caused by all known subtypes of hepatitis B virus.

CONTRAINDICATIONS

Hypersensitivity to yeast or any component of the vaccine.

WARNINGS

Patients who develop symptoms suggestive of hypersensitivity after an injection should not receive further injections of the vaccine (see CONTRAINDICATIONS).

Because of the long incubation period for hepatitis B, it is possible for unrecognized infection to be present at the time the vaccine is given. The vaccine may not prevent hepatitis B in such patients.

PRECAUTIONS

General
As with any percutaneous vaccine, epinephrine should be available for immediate use should an anaphylactoid reaction occur.

Any serious active infection is reason for delaying use of the vaccine except when in the opinion of the physician, withholding the vaccine entails a greater risk.

Caution and appropriate care should be exercised in administering the vaccine to individuals with severely compromised cardiopulmonary status or to others in whom a febrile or systemic reaction could pose a significant risk.

Pregnancy
Pregnancy Category C: Animal reproduction studies have not been conducted with the vaccine. It is also not known whether the vaccine can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. The vaccine should be given to a pregnant woman only if clearly needed.

Nursing Mothers
It is not known whether the vaccine is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when the vaccine is administered to a nursing woman.

Pediatric Use
RECOMBIVAX HB has been shown to be usually well-tolerated and highly immunogenic in infants and children of all ages. Newborns also respond well; maternally transferred antibodies do not interfere with the active immune response to the vaccine. See DOSAGE AND ADMINISTRATION in full Prescribing Information for recommended pediatric dosage and for recommended dosage for infants born to HBsAg positive mothers.

The safety and effectiveness of RECOMBIVAX HB Dialysis Formulation in children have not been established.

ADVERSE REACTIONS

RECOMBIVAX HB and RECOMBIVAX HB Dialysis Formulation are generally well-tolerated. No serious adverse reactions attributable to the vaccine have been reported during the course of clinical trials. No adverse experiences were reported during clinical trials which could be related to changes in the titers of antibodies to yeast. As with any vaccine, there is the possibility that broad use of the vaccine could reveal adverse reactions not observed in clinical trials.

In a group of studies, 1636 doses of RECOMBIVAX HB were administered to 653 healthy infants and children (up to 10 years of age) who were monitored for 5 days after each dose. Injection site reactions (including erythema and swelling) and systemic complaints were reported following 8% and 17% of the injections, respectively. The most frequently reported systemic adverse reactions (>1% injections), in decreasing order of frequency, were irritability, tiredness, fever (>100°F oral equivalent), crying, diarrhea, vomiting, diminished appetite, and insomnia.

In a group of studies, 2582 doses of RECOMBIVAX HB were administered to 1252 healthy adults who were monitored for 5 days after each dose. Injection site and systemic complaints were reported following 17% and 15% of the injections, respectively. The following adverse reactions were reported:

Incidence Equal to or Greater Than 1% of Injections

LOCAL REACTION (INJECTION SITE)
Injection site reactions consisting principally of soreness, and including pain, tenderness, pruritus, erythema, ecchymosis, swelling, warmth, and nodule formation.

BODY AS A WHOLE
The most frequent systemic complaints include fatigue/weakness; headache; fever (≥100°F); and malaise.

DIGESTIVE SYSTEM
Nausea; and diarrhea

RESPIRATORY SYSTEM
Pharyngitis; and upper respiratory infection

Incidence Less Than 1% of Injections

BODY AS A WHOLE
Sweating; achiness; sensation of warmth; lightheadedness; chills; and flushing

DIGESTIVE SYSTEM
Vomiting; abdominal pain/cramps; dyspepsia; and diminished appetite

RESPIRATORY SYSTEM
Rhinitis; influenza; and cough

NERVOUS SYSTEM
Vertigo/dizziness; and paresthesia

INTEGUMENTARY SYSTEM
Pruritus; rash (non-specified); angioedema; and urticaria

MUSCULOSKELETAL SYSTEM
Arthritis including monoarticular; myalgia; back pain; neck pain; shoulder pain; and neck stiffness

HEMIC/LYMPHATIC SYSTEM
Lymphadenopathy

PSYCHIATRIC/BEHAVIORAL
Insomnia/disturbed sleep

SPECIAL SENSES
Earache

UROGENITAL SYSTEM
Dysuria

CARDIOVASCULAR SYSTEM
Hypotension

Marketed Experience
The following additional adverse reactions have been reported with use of the marketed vaccine. In many instances, the relationship to the vaccine was unclear.

Hypersensitivity
Anaphylaxis and symptoms of immediate hypersensitivity reactions including rash, pruritus, urticaria, edema, angioedema, dyspnea, chest discomfort, bronchial spasm, palpitation, or symptoms consistent with a hypotensive episode have been reported within the first few hours after vaccination. An apparent hypersensitivity syndrome (serum sickness-like) of delayed onset has been reported days to weeks after vaccination, including: arthralgia/arthritis (usually transient), fever, and dermatologic reactions such as urticaria, erythema multiforme, ecchymoses and erythema nodosum (see WARNINGS and PRECAUTIONS).

Digestive System
Elevation of liver enzymes; constipation.

Nervous System
Guillain-Barré Syndrome; multiple sclerosis; myelitis including transverse myelitis; peripheral neuropathy including Bell's Palsy; radiculopathy; herpes zoster; migraine; muscle weakness; hypotension.

Integumentary System
Steven-Johnson Syndrome; petechiae.

Musculoskeletal System
Arthritis.

Hematologic
Increased erythrocyte sedimentation rate; thrombocytopenia.

Immune System
Lupus-like syndrome.

Psychiatric/Behavioral
Irritability; agitation; somnolence.

Special Senses
Optic neuritis; tinnitus; conjunctivitis; visual disturbances.

Cardiovascular System
Syncope, tachycardia.

The following adverse reaction has been reported with another Hepatitis B Vaccine (Recombinant) but not with RECOMBIVAX HB: keratitis.
Help Eradicate Hepatitis B

Use the only vaccine with a concentrated 40 mcg/mL dose precisely formulated for predialysis and dialysis patients

Recombivax HB®
(Hepatitis B Vaccine [Recombinant])

The Vision and Precision
to Help End Hepatitis B

RECOMBIVAX HB is contraindicated in the presence of hypersensitivity to yeast or to any component of the vaccine. Patients who develop symptoms suggestive of hypersensitivity after an injection should not receive further injections of the vaccine.
RECOMBIVAX HB Dialysis Formulation (40 mcg/mL) is intended only for adult predialysis/dialysis patients.
A booster dose or revaccination may be considered if the anti-HBs level is less than 10 mIU/mL 1–2 months after the third dose.
Please read the Brief Summary of the Prescribing Information accompanying this advertisement.